Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.

[1]  V. Jairath,et al.  Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy. , 2020, Inflammatory bowel diseases.

[2]  J. Casanova,et al.  Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee , 2020, Journal of Clinical Immunology.

[3]  S. Ehl,et al.  The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. , 2019, The journal of allergy and clinical immunology. In practice.

[4]  A. Ristimäki,et al.  A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency , 2019, The American journal of gastroenterology.

[5]  G. Corazza,et al.  The high mortality of patients with common variable immunodeficiency and small bowel villous atrophy , 2019, Scandinavian journal of gastroenterology.

[6]  M. Valasek,et al.  Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation , 2017, The American Journal of Gastroenterology.

[7]  K. Warnatz,et al.  Increase of circulating α4β7+ conventional memory CD4 and regulatory T cells in patients with common variable immunodeficiency (CVID). , 2017, Clinical immunology.

[8]  M. Mehling,et al.  Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. , 2017, The Journal of allergy and clinical immunology.

[9]  T. Karlsen,et al.  A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms and Pathology in Patients With Common Variable Immunodeficiency , 2016, The American Journal of Gastroenterology.

[10]  V. Pascual,et al.  Expansion of inflammatory innate lymphoid cells in patients with common variable immune deficiency. , 2016, The Journal of allergy and clinical immunology.

[11]  C. Cunningham-Rundles,et al.  Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD) , 2016, Current Gastroenterology Reports.

[12]  É. Oksenhendler,et al.  Clinical picture and treatment of 2212 patients with common variable immunodeficiency. , 2014, The Journal of allergy and clinical immunology.

[13]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[14]  B. Oldenburg,et al.  Outcome of screening endoscopy in common variable immunodeficiency disorder and X-linked agammaglobulinemia , 2013, Endoscopy.

[15]  M. Ziol,et al.  The Enteropathy Associated With Common Variable Immunodeficiency: The Delineated Frontiers With Celiac Disease , 2010, The American Journal of Gastroenterology.

[16]  Lennart Hammarstrom,et al.  Common variable immunodeficiency disorders: division into distinct clinical phenotypes. , 2008, Blood.

[17]  E. Montgomery,et al.  Gastrointestinal Tract Pathology in Patients With Common Variable Immunodeficiency (CVID): A Clinicopathologic Study and Review , 2007, The American journal of surgical pathology.

[18]  P. Mannon,et al.  Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. , 2006, Gastroenterology.

[19]  K. Washington,et al.  Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. , 1996, The American journal of surgical pathology.

[20]  C. Cunningham-Rundles,et al.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. , 2016, The journal of allergy and clinical immunology. In practice.

[21]  J. Stockman.  Morbidity and mortality in common variable immune deficiency over 4 decades , 2013 .